Syrigos, Konstantinos
Abert, Istvan
Andric, Zoran
Bondarenko, Igor N
Dvorkin, Mikhail
Galic, Kristina
Galiulin, Rinat
Kuchava, Vladimer
Sriuranpong, Virote
Trukhin, Dmytro
Zhavrid, Edvard
Fu, Dongyue
Kassalow, Laurent M
Jones, Stephanie
Bashir, Zahid
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
https://doi.org/10.1007/s40259-021-00489-4
Funding for this research was provided by:
Centus Biotherapeutics, Ltd.
Article History
Accepted: 29 May 2021
First Online: 15 July 2021
Declarations
:
: This study was funded by Centus Biotherapeutics.
: Doctors Syrigos, Abert, Andric, Bondarenko, Dvorkin, Galic, Galiulin, Kuchava, Sriuranpong, Trukhin, and Zhavrid received research support from Centus Biotherapeutics for the conduct of the AVANA trial. Dr. Fu is an employee of AstraZeneca. Mr. Kassalow and Doctors Bashir and Jones are consultants to Centus Biotherapeutics.
: This study was approved by the individual institutional review boards of the study sites and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: All patients gave informed consent to participate in the trial.
: Data are posted on ExternalRef removed and can be accessed at: ExternalRef removed.
: The manuscript was developed under the primary guidance of Drs. Syrigos, Bashir, Fu, and Kassalow. All authors reviewed the manuscript at each stage and provided significant direction on the interpretation of the data and its significance.